Merck Withdraws Biologics License Application for Patritumab Deruxtecan-February 2024-www.financetom.com

Merck Withdraws Biologics License Application for Patritumab Deruxtecan

News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities

Merck Withdraws Biologics License Application for Patritumab Deruxtecan

May 29, 2025 5:18 AM

07:45 AM EDT, 05/29/2025 (MT Newswires) -- Merck & Co. ( MRK ) said Thursday that it has voluntarily withdrawn its biologics license application with Daiichi Sankyo seeking approval for patritumab deruxtecan in the US.

The application was based on the HERTHENA-Lung01 phase 2 trial for the treatment of certain adult patients with non-small cell lung cancer.

The company said it decided to withdraw the application because the topline overall survival results from the confirmatory HERTHENA-Lung02 phase 3 trial did not meet statistical significance.

Previous page： Form 8.3 Next page： Navan to be Frasers Group's Global Partner for Travel, Expense Management

Comments

Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.

Show More Comments

Related Articles >

Form 8.3

Nov 24, 2025

LONDON--(BUSINESS WIRE)-- FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the “Code”) 1. KEY INFORMATION (a) Full name of discloser: Qube Research & Technologies Limited (b) Owner or controller of interests and short positions disclosed, if different from 1(a): The naming of...

Navan to be Frasers Group's Global Partner for Travel, Expense Management

Nov 24, 2025

05:46 AM EST, 11/24/2025 (MT Newswires) -- Navan (NAVN) said Monday it will be Frasers Group's global partner for travel and expense management. Frasers' team members will use the Navan platform to book travel and submit expenses in one place, enabling automatic travel payment and expense reconciliation. ...

Form 8.3

Nov 24, 2025

EU approves Omnicom's acquisition of IPG without conditions

Nov 24, 2025

BRUSSELS (Reuters) -The EU Commission on Monday said it had unconditionally approved Omnicom Group's ( OMC ) $13.25 billion all-stock deal to buy rival Interpublic Group. The deal, announced last December, merges the world's third-largest ad buyer, Omnicom ( OMC ), with the fourth-largest which is Interpublic. It would create the world's largest advertising agency as traditional players look to...